Nat Rev Drug Discov. 2024 Dec 12. IF: 122.7
Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer.
www.nature.com/articles/s41573-024-01098-w
N Engl J Med. 2024 Dec 12. IF: 96.2
Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial.
www.nejm.org/doi/10.1056/NEJMoa2412063
N Engl J Med. 2024 Dec 12. IF: 96.2
Sentinel-Lymph-Node Biopsy in Early-Stage Breast Cancer - Is It Obsolete?
www.nejm.org/doi/10.1056/NEJMe2414899
Nat Rev Mol Cell Biol. 2024 Dec 12. IF: 81.3
Modelling human brain development and disease with organoids.
www.nature.com/articles/s41580-024-00804-1
JAMA. 2024 Dec 12. IF: 63.1
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial.
www.jamanetwork.com/journals/jama/fullarticle/2828218
JAMA. 2024 Dec 12. IF: 63.1
Is It Time to Abandon Surgery for Low-Risk DCIS?
www.jamanetwork.com/journals/jama/fullarticle/2828219
JAMA. 2024 Dec 12. IF: 63.1
Am I a Survivor?
www.jamanetwork.com/journals/jama/fullarticle/2827948
J Clin Oncol. 2024 Dec 12. IF: 42.1
Development and Validation of Data-Driven Estimates of Recurrence Risk and Treatment Benefit in Early Breast Cancer.
www.ascopubs.org/doi/10.1200/JCO-24-02452
Lancet Oncol. 2024 Dec 12. IF: 41.6
Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial.
www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00661-2
Lancet Oncol. 2024 Dec 12. IF: 41.6
Optimising therapy and avoiding overtreatment in breast cancer.
www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00707-1
JAMA Oncol. 2024 Dec 12. IF: 22.5
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial.
www.jamanetwork.com/journals/jamaoncology/fullarticle/2828196
JAMA Oncol. 2024 Dec 12. IF: 22.5
Bilateral Mastectomy vs Lumpectomy and Breast Cancer Mortality Risk.
www.jamanetwork.com/journals/jamaoncology/fullarticle/2827889
JAMA Oncol. 2024 Dec 12. IF: 22.5
Bilateral Mastectomy vs Lumpectomy and Breast Cancer Mortality Risk-Reply.
www.jamanetwork.com/journals/jamaoncology/fullarticle/2827888
JAMA Oncol. 2024 Dec 12. IF: 22.5
Second Primary Cancer After Chimeric Antigen Receptor-T-Cell Therapy: A Review.
www.jamanetwork.com/journals/jamaoncology/fullarticle/2827886
Drug Resist Updat. 2024 Dec 6. IF: 15.8
Fasting-mimicking diet potentiates anti-tumor effects of CDK4/6 inhibitors against breast cancer by suppressing NRAS- and IGF1-mediated mTORC1 signaling.
www.sciencedirect.com/science/article/pii/S1368764624001407
Acta Pharm Sin B. 2024 Nov 22;14(11):4806-4818. IF: 14.7
A novel shark VNAR antibody-based immunotoxin targeting TROP-2 for cancer therapy.
www.sciencedirect.com/science/article/pii/S2211383524003423
J Am Chem Soc. 2024 Dec 12. IF: 14.4
Engineering a Near-Infrared Spiro-Based Aggregation-Induced Emission Luminogen for DNAzyme-Sensitized Photothermal Therapy with High Efficiency and Accuracy.
pubs.acs.org/doi/10.1021/jacs.4c14818
Trends Cancer. 2024 Dec 12. IF: 14.3
Artificial intelligence improves mammography-based breast cancer risk prediction.
www.cell.com/trends/cancer/fulltext/S2405-8033(24)00226-7
Lancet Reg Health Eur. 2024 Dec 12;47:101160. IF: 13.6
Internal mammary node irradiation in 4541 node-positive breast cancer patients treated with newer systemic therapies and 3D-based radiotherapy (DBCG IMN2): a prospective, nationwide, population-based cohort study.
www.thelancet.com/journals/lanepe/article/PIIS2666-7762(24)00329-6
J Natl Cancer Inst. 2024 Dec 12. IF: 9.9
Evaluating the performance of the BOADICEA model in predicting 10-year breast cancer risks in UK Biobank.
www.academic.oup.com/jnci/article/7922560
Cancer Treat Rev. 2025 Jan;132:102861. IF: 9.6
PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer.
www.cancertreatmentreviews.com/article/S0305-7372(24)00190-7/fulltext